Tesaro has rolled out its ovarian cancer drug Zejula—and unveiled its so-far-secret list price, $9,833 per month. That looks like a discount to AZ's rival…

UniQure's trailblazing gene therapy has met its end. After struggling for years with the ultraexpensive Glybera, the company is calling it quits on the…

It was destined to happen: Amgen has sued Sanofi and Regeneron, claiming their newly approved Dupixent infringes one of its antibody patents.

Pharma largely continued its price-hiking ways in 2016, and no wonder: The corresponding sales windfall equated to 100% of the industry’s overall earnings-per-…

To partner or not to partner on a new drug launch? Of all the decisions emerging biopharma companies have to make, that's among the most important.

Pfizer's Xeljanz is an obvious beneficiary of Eli Lilly's surprise Olumiant (baricitinib) rejection at the FDA. But AbbVie and Gilead could gain, too.

Novo Nordisk is looking to boost its fortunes with a new insulin launch in European countries and elsewhere.

It’s no secret that Roche’s new multiple sclerosis med, Ocrevus, will pile pressure on the existing meds in the field. But how much pressure? One analyst has…

BMS Chief Giovanni Caforio got a 10% salary hike in 2016—a year when immuno-oncology star Opdivo grew by billions but failed a key trial.

Launches